Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Wyeth Enters Hemophilia R&D Pacts | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Wyeth Enters Hemophilia R&D Pacts

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Wyeth Pharmaceuticals signed a research collaboration with MediVas, LLC, a biomaterials company specializing in improved delivery of biologics. This collaboration was initiated to discover, develop, manufacture and commercialize biopharmaceuticals that extend the duration of action of recombinant factor treatments for hemophilia. MediVas will use a polymer-based drug delivery system to develop advanced delivery methods to create a longer half-life for these proteins.

Under the terms of the agreement, MediVas will receive milestone payments associated with development, regulatory filings and approvals and royalty payments based on product sales. Wyeth will research, develop, manufacture and market any products that result from the agreement.

Wyeth has also signed a research collaboration and license agreement with Nautilus Biotech to discover and develop novel recombinant Factor IX proteins for hemophilia B. These extended half-life proteins will also be designed to enhance patient convenience by reducing the number and frequency of treatments needed.

As part of the agreement, Nautilus will apply its proprietary technology to improve the duration of action of recombinant hemophilia B therapy. This technology makes minimal and specific changes to the amino acid sequence in order to slow the breakdown of the protein in the body.

Wyeth will develop, manufacture and market products derived from the collaboration. Nautilus will receive an upfront payment, R&D fees, milestone payments associated with development, regulatory filings and approvals, and royalty payments based on product sales.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics